山东医药2025，Vol.65Issue(7)：124-127,4.DOI:10.3969/j.issn.1002-266X.2025.07.026
1例转移性去势抵抗性前列腺癌合并糖尿病的治疗
Treatment of one case of metastatic castration-resistant prostate cancer complicated with diabetes mellitus
摘要
Abstract
Objective To summarize the effective treatment method for metastatic castration-resistant prostate can-cer(mCRPC)with concurrent diabetes,providing a reference for individualized treatment plan.Methods A retrospec-tive analysis of the treatment process of a patient with mCRPC and concurrent diabetes was conducted.Results A 77-year-old male patient diagnosed with prostate cancer in 2018,with lung and bone metastases,achieved a partial remission after treatment with bicalutamide+zoladex+zoledronic acid injection.Due to the patient's intermittent oral medication use,the disease progressed to mCRPC in July 2021,and the treatment regimen was adjusted to abiraterone+prednisone.One month after treatment,due to poor glycemic control,the treatment regimen was changed to enzalutamide+zoladex+zoledronic acid injection.Subsequently,prostate-specific antigen(PSA)gradually decreased,reaching 0 on October 9,2022.A follow-up examination in July 2024 showed that the patient's PSA remained at 0,the primary lesion and metastat-ic tumors had significantly shrunk compared to before,bone metastases had improved,glycemic control was good,and there were no adverse reactions.Conclusion For mCRPC patients with concurrent diabetes,treatment with enzaluta-mide is safe and effective,and does not affect glycemic control.关键词
恩杂鲁胺/前列腺癌/转移性去势抵抗性前列腺癌/糖尿病/阿比特龙/比卡鲁胺Key words
enzalutamide/prostatic carcinoma/metastatic castration-resistant prostate cancer/diabetes mellitus/abiraterone/bicalutamide分类
医药卫生引用本文复制引用
张春雷,康印东..1例转移性去势抵抗性前列腺癌合并糖尿病的治疗[J].山东医药,2025,65(7):124-127,4.基金项目
甘肃省卫生健康委课题项目(GSWSKY2023-46). （GSWSKY2023-46）
